UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the Month of September, 2016

 

Commission File Number: 001-35892

 

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x       Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨       No ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨       No ¨

 

 

Other Events

 

On September 14, 2016, GW Pharmaceuticals plc (the “Company”) issued a regulatory news service (“RNS”) announcement with details of the exercise by Dr Stephen Wright of options to acquire 198,288 0.1 pence ordinary shares of the Company for an average exercise price of 28.15 pence per share. These shares were immediately converted into 16,524 American Depositary Shares (“ADSs”) and sold on the Nasdaq Global Market for an average price of $98.75 per ADS. The sale represents less than 0.1% of the Company’s shares in issue. The RNS is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information contained in the RNS shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

 

 

Exhibits
99.1	Regulatory new service announcement dated September 14, 2016

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	GW Pharmaceuticals plc
	By:	/s/ Adam George
	Name:	Adam George
	Title:	Chief Financial Officer
Date: September 14, 2016